MUMBAI: Wockhardt Group Chairman Dr. Habil Khorakiwala has been conferred with the prestigious Degree of Doctor of Literature (D. Litt.) by the Kalinga Institute of Industrial Technology (KIIT) University, Bhubaneswar, at the University’s 12th Annual Convocation ceremony. Sir Richard J Roberts, Nobel laureate, physiology/medicine (1993) was also conferred a Degree of Doctor of Science (DSc) on the occasion.
Expressing his gratitude, Dr. Khorakiwala said, “On behalf of the entire Wockhardt team, I would like to thank the KIIT University for this honour. It will inspire us to contribute more for the larger society.”
Dr. Khorakiwala holds an Honorary Doctorate from Purdue University, USA. He was the first non-American to have received this recognition, since the university was established 125 years ago. The University has also conferred Dr. Khorakiwala with the title of ‘Distinguished Alumnus’ for significant contribution to the field of pharmacy.
In 2014, Jamia Hamdard University, a New Delhi-based reputed educational institute, appointed the Wockhardt Chairman as its Chancellor. Presently, Dr. Habil Khorakiwala is the Chairman at Centre of Organisation Development (COD), a not-for-profit management education institution in Hyderabad.
Dr. Khorakiwala completed his education in pharmacy from the L M College in Ahmedabad. He later acquired a Masters Degree in pharmaceutical science from Purdue University, and thereafter completed an Advanced Management Programme at the Harvard Business School.
Wockhardt is a Global Pharmaceutical company employing over 10,000 people from 27 nationalities with presence in USA, UK, Ireland, Mexico, Russia and many other countries. It has manufacturing and research facilities in India, USA & UK and a manufacturing facility in Ireland. Wockhardt has a significant presence in USA, Europe and India, with 61% of its global revenues coming from international businesses.
Wockhardt is home to 850 scientists, of whom 100 are doctorates. Wockhardt is the only company in the world where USFDA has given QIDP Status (Qualified Infectious Diseases Programme) for 5 of our Anti-bacterial discovery programmes – 2 of them are Gram Negative and 3 Gram Positive.